AbbVie and Gilgamesh ally the discovery and development of Next-Gen Psychiatric Therapies

AbbVie and Gilgamesh Pharmaceuticals have collaborated and signed an option-to-license agreement to develop next-generation therapies to treat psychiatric disorders, as reported. This alliance will leverage AbbVie’s expertise in psychiatry and Gilgamesh’s research platform to discover new neuroplastogens. 

According to the agreement, companies shall focus on researching and developing a portfolio of next-gen therapeutics. This agreement also gives AbbVie the right to commercialise these therapeutics.  Gilgamesh will receive an upfront payment of $65 million and could earn up to $1.95 billion in total option fees, milestones, and royalties on future sales.

Neuroplastogens are the next-generation psychedelic compounds that can target the mechanisms showing the potential to provide notable clinical benefits and reduce the side effects of first-generation compounds, like hallucination. These new compounds are showing promising results in treating psychiatric conditions like mood swings and anxiety disorders. Gilgamesh 

These new compounds hold promise for treating a variety of psychiatric conditions, including mood and anxiety disorders. The successful discovery of these new compounds is attributed to the innovative platform Gilgamesh used. 

The senior Vice President and Global Head of Discovery Research, Jonathan Sedgwick, PhD, at AbbVie, says, “Significant unmet need remains for people living with psychiatric disorders, and we know that to innovate in this field, we need to pursue novel technologies and approaches,” 

“We look forward to working with Gilgamesh’s world-class team to advance the development of novel neuroplastogens and pave the way for additional treatment approaches in psychiatry.”